Stable Istotope Labelled Bevacizumab Biosimilar – Anti-VEGF mAb – Research Grade

Reference: PX-TA1006-SIL-1MG
Product nameStable Istotope Labelled Bevacizumab Biosimilar - Anti-VEGF mAb - Research Grade
SourceDrugBank DB00112
Expression systemMammalian cells
Molecular weight149kDa
BufferPBS pH7.5
Delivery conditionBlue Ice
Delivery Time3-5 days if in stock; 5-8 weeks if production needed
Storage condition4°C for short term; -20°C for long term
Aliases /SynonymsBevacizumab
Related ProductsPX-P1167
NoteFor research use only. Not suitable for clinical or therapeutic use.
ClonalityMonoclonal Antibody
SourceDrugBank DB00112
LabellingArginine: 13C6,15N4 ; Lysine: 13C6,15N2, >99%
Isotopic Enrichment99%
Stability1 year

General information about Bevacizumab

Bevacizumab, is classified as a monoclonal antibody and/or anti-angiogenesis drug. It is a comparatively new type of cancer therapy. Antibodies are an essential part of the immune system. The body creates antibodies in response to an antigen entering the body. These antibodies attach themselves to the antigen, to mark it for destruction by the body’s immune system. Bevacizumab allows human body to target specific cells, causing less toxicity to healthy cells. It works by interfering with the process of angiogenesis by targeting and inhibiting human vascular endothelial growth factor (VEGF). VEGF is a cytokine (a small protein released by cells that have specific effects on the behavior of cells) which when it interacts with its receptors in the cell leads to new blood vessel formation or angiogenesis. This product is for research use only.


There are no reviews yet.


Be the first to review “Stable Istotope Labelled Bevacizumab Biosimilar – Anti-VEGF mAb – Research Grade”

Your email address will not be published. Required fields are marked *

Contact us

Got a question or need a quote?
Message us and we’ll get back to you 48 hours or less.